Biology of angiotensin II receptor inhibition with a focus on losartan: A new drug for the treatment of hypertension

Expert Opinion on Investigational Drugs

Volumn 5, Issue 9, 1996, Pages 1201-1214

  Tallant, E A ^a   Ferrario, C M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin II; Angiotensin receptor subtypes; Angiotensin (1 7); Angiotensin (2 8); Angiotensinogen; Congestive heart failure; DuP 753; Essential hypertension; Losartan; MK 954; Renin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN POTASSIUM;

ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG SPECIFICITY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HUMAN; KIDNEY FAILURE; NONHUMAN; ORAL DRUG ADMINISTRATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; VERTIGO;

EID: 0029773902     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.5.9.1201     Document Type: Review

References (0)